Verrica Reports Q4 Revenue of $5.092M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy VRCA?
Reports 4Q revenue $5.092M, consensus $4.52M. "In 2025, Verrica successfully implemented a series of transformational changes that we believe have fundamentally improved the future growth and strategic value of our entire business," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "Our focused and efficient commercial strategy allowed us to nearly double dispensed applicator units of YCANTH from the prior year while cutting selling, general and administrative expenses by over 40% over that same period. This February, we dispensed more applicators of YCANTH per selling day than in any month in our history, reflecting strong and increasing demand for YCANTH. We are poised to advance our late-stage clinical pipeline in common warts and basal cell carcinoma, which collectively could represent a multiple billion-dollar opportunity. Finally, in 2025 we significantly improved our financial position, repaying our outstanding debt while extending our cash runway into the first quarter of 2027."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRCA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRCA
Wall Street analysts forecast VRCA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.950
Low
17.00
Averages
18.67
High
20.00
Current: 6.950
Low
17.00
Averages
18.67
High
20.00
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verrica Pharmaceuticals Q1 2026 Earnings Call Highlights
- Market Demand Growth: Verrica Pharmaceuticals reported total revenue of $5 million in Q1 2026, with $4.3 million from U.S. net YCANTH revenue, indicating accelerating market demand for YCANTH, particularly with record dispensed applicator units in March, which enhances the company's competitive position in the market.
- Japanese Market Expansion: YCANTH was successfully launched in Japan in February as a product of Torii Pharmaceutical, marking a significant milestone that not only begins to offset Verrica's clinical costs but also lays the groundwork for future international expansion, demonstrating the company's strategic positioning in global markets.
- Clinical Trial Progress: The company has achieved over 50% enrollment in the first Phase III trial, COVE-2, and plans to initiate the second Phase III trial, COVE-3, by mid-2026, providing strong support for product market approval and boosting investor confidence in the company's pipeline.
- Strong Financial Position: As of March 31, 2026, Verrica had $20.6 million in cash, expected to fund operations into Q1 2027, and despite a GAAP net loss of $9.7 million, the company reported a gross product margin of 87.3%, indicating strong potential for profitability.
See More
Verrica Presents Phase 2 Data for VP-315 Indicating Abscopal Effect in BCC Treatment
- Phase 2 Data Presentation: Verrica Therapeutics presented Phase 2 data for VP-315 at the Society for Investigative Dermatology annual meeting on May 15, 2026, indicating its potential efficacy in treating basal cell carcinoma (BCC), which is the most common cancer in the U.S. with 36 million new cases diagnosed annually.
- Non-Surgical Treatment Option: VP-315, a novel oncolytic peptide immunotherapy, is administered directly to tumors, inducing immunogenic cell death and providing a non-surgical alternative to traditional surgical excisions, thereby reducing patient risks associated with surgery.
- Observed Abscopal Effect: In the Phase 2 open-label study, non-treated lesions (NTLs) showed a 67% reduction in size over 12 weeks, with 21% achieving complete histological clearance, suggesting that VP-315 may trigger an abscopal effect through broader immune activation within the tumor microenvironment.
- Exploration of Multiple Indications: VP-315 is also being investigated for various oncological indications, including non-metastatic melanoma and squamous cell carcinoma, and has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 trials, enhancing its market potential.
See More
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
See More
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
See More
Verrica Pharmaceuticals Reports Strong Revenue Growth Despite EPS Miss
- Earnings Highlights: Verrica Pharmaceuticals reported a FY Non-GAAP EPS of -$1.24, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Significant Revenue Growth: The company achieved revenues of $35.58 million, representing a 370.6% year-over-year increase, surpassing market expectations by $0.58 million, reflecting strong product demand and market share gains.
- Market Reaction: Despite the EPS miss, the robust revenue growth may generate positive sentiment among investors, enhancing confidence in the company's future prospects.
- Strategic Outlook: Verrica's financial performance highlights its potential in the pharmaceutical industry, particularly in terms of new product launches and market expansion, which could lay the groundwork for future investments and growth.
See More
Verrica Initiates Global Phase 3 Trial for YCANTH, Targeting Multibillion-Dollar Market
- Clinical Milestone: Verrica successfully dosed the first patient in December 2025 for its global Phase 3 trial of YCANTH, marking a significant advancement in treating common warts, with the potential to become the first approved therapy in both the U.S. and Japan, addressing the urgent needs of 22 million patients.
- Market Opportunity: With approximately 22 million patients in the U.S. alone, Verrica estimates that the common warts market could represent a multibillion-dollar opportunity, particularly as nearly 50% of these patients are children, indicating strong market potential and future growth prospects.
- Financial Backing: Verrica's recent completion of a $50 million financing and repayment of its debt to OrbiMed provides essential funding for the continued development of YCANTH, enhancing the company's competitive position in the market.
- Cost-Sharing Partnership: Verrica will share the costs of the global Phase 3 trial with Torii, which will fund the first $40 million of trial expenses, approximately 90% of the current budget, alleviating Verrica's financial burden and accelerating the clinical timeline.
See More
Verrica Pharmaceuticals Q1 2026 Earnings Call Highlights
- Market Demand Growth: Verrica Pharmaceuticals reported total revenue of $5 million in Q1 2026, with $4.3 million from U.S. net YCANTH revenue, indicating accelerating market demand for YCANTH, particularly with record dispensed applicator units in March, which enhances the company's competitive position in the market.
- Japanese Market Expansion: YCANTH was successfully launched in Japan in February as a product of Torii Pharmaceutical, marking a significant milestone that not only begins to offset Verrica's clinical costs but also lays the groundwork for future international expansion, demonstrating the company's strategic positioning in global markets.
- Clinical Trial Progress: The company has achieved over 50% enrollment in the first Phase III trial, COVE-2, and plans to initiate the second Phase III trial, COVE-3, by mid-2026, providing strong support for product market approval and boosting investor confidence in the company's pipeline.
- Strong Financial Position: As of March 31, 2026, Verrica had $20.6 million in cash, expected to fund operations into Q1 2027, and despite a GAAP net loss of $9.7 million, the company reported a gross product margin of 87.3%, indicating strong potential for profitability.
See More
Verrica Presents Phase 2 Data for VP-315 Indicating Abscopal Effect in BCC Treatment
- Phase 2 Data Presentation: Verrica Therapeutics presented Phase 2 data for VP-315 at the Society for Investigative Dermatology annual meeting on May 15, 2026, indicating its potential efficacy in treating basal cell carcinoma (BCC), which is the most common cancer in the U.S. with 36 million new cases diagnosed annually.
- Non-Surgical Treatment Option: VP-315, a novel oncolytic peptide immunotherapy, is administered directly to tumors, inducing immunogenic cell death and providing a non-surgical alternative to traditional surgical excisions, thereby reducing patient risks associated with surgery.
- Observed Abscopal Effect: In the Phase 2 open-label study, non-treated lesions (NTLs) showed a 67% reduction in size over 12 weeks, with 21% achieving complete histological clearance, suggesting that VP-315 may trigger an abscopal effect through broader immune activation within the tumor microenvironment.
- Exploration of Multiple Indications: VP-315 is also being investigated for various oncological indications, including non-metastatic melanoma and squamous cell carcinoma, and has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 trials, enhancing its market potential.
See More
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
See More
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
See More
Verrica Pharmaceuticals Reports Strong Revenue Growth Despite EPS Miss
- Earnings Highlights: Verrica Pharmaceuticals reported a FY Non-GAAP EPS of -$1.24, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Significant Revenue Growth: The company achieved revenues of $35.58 million, representing a 370.6% year-over-year increase, surpassing market expectations by $0.58 million, reflecting strong product demand and market share gains.
- Market Reaction: Despite the EPS miss, the robust revenue growth may generate positive sentiment among investors, enhancing confidence in the company's future prospects.
- Strategic Outlook: Verrica's financial performance highlights its potential in the pharmaceutical industry, particularly in terms of new product launches and market expansion, which could lay the groundwork for future investments and growth.
See More
Verrica Initiates Global Phase 3 Trial for YCANTH, Targeting Multibillion-Dollar Market
- Clinical Milestone: Verrica successfully dosed the first patient in December 2025 for its global Phase 3 trial of YCANTH, marking a significant advancement in treating common warts, with the potential to become the first approved therapy in both the U.S. and Japan, addressing the urgent needs of 22 million patients.
- Market Opportunity: With approximately 22 million patients in the U.S. alone, Verrica estimates that the common warts market could represent a multibillion-dollar opportunity, particularly as nearly 50% of these patients are children, indicating strong market potential and future growth prospects.
- Financial Backing: Verrica's recent completion of a $50 million financing and repayment of its debt to OrbiMed provides essential funding for the continued development of YCANTH, enhancing the company's competitive position in the market.
- Cost-Sharing Partnership: Verrica will share the costs of the global Phase 3 trial with Torii, which will fund the first $40 million of trial expenses, approximately 90% of the current budget, alleviating Verrica's financial burden and accelerating the clinical timeline.
See More
